Stephen Opat

Stephen Opat is an Adjunct Clinical Professor at Monash Health, leading the Clinical Haematology service, which serves approximately 1.3 million patients and integrates evidence-based care with research. His key areas include lymphoid cancer, chronic myeloid disorders, and novel therapies. He is the principal investigator in over 30 clinical trials, particularly in lymphoid malignancies, and founded the Australasian Lymphoma and Related Diseases Registry. He actively participates in organizations like the Haematology Society of Australia and New Zealand (current President). His research focuses on lymphoma, chronic lymphocytic leukaemia (CLL), and genomics, with a strong emphasis on clinical trials and translational medicine.

Research Interests

• Diagnosis and management of lymphoma and CLL
• Cancer genomics and precision medicine
• Novel therapies for hematologic malignancies
• Iron metabolism disorders and Gaucher disease
• Medical education, especially in developing regions

Recent Articles Trends

Recent work emphasizes clinical trials evaluating BTK inhibitors (e.g., zanubrutinib) and BCL2 inhibitors, focusing on efficacy, safety, and long-term outcomes in CLL, Waldenström macroglobulinemia, and lymphoma subtypes. Studies also explore biomarkers and treatment combinations, such as sonrotoclax with zanubrutinib for refractory cases. Research highlights real-world outcomes, patient survival, and disparities in access to therapies.

Grants & Advising

• Principal Investigator in 51+ projects since 2010, including Phase III trials for novel therapies
• Leadership in global registries and collaborative networks

Labs & Teams

Active collaborations with institutions like the Monash Health Translation Precinct (MHTP), Hudson Institute’s Centre for Cancer Research, and the Australasian Leukaemia and Lymphoma Group.